). However, the features of the drug that contribute to its activity towards mammalian systems have not been characterized. Therefore, CP-115,953 and a series of related quinolones were examined for their activity against calf thymus topoisomerase H and cultured mammalian cells. CP-115,953 stimulated DNA cleavage mediated by the type H enzyme with a potency that was -600-fold greater than that of the antimicrobial quinolone ciprofloxacin and -50-fold greater than that of the antineoplastic drug etoposide. As determined by the ability to enhance enzyme-mediated DNA cleavage, quinolone activity towards calf thymus topoisomerase H was enhanced by the presence of a cyclopropyl group at the N-1 ring position and by the presence of a fluorine at C-8. Furthermore, the 4'-hydroxyphenyl substituent at the C-7 position was critical for the potency of CP-115,953 towards the mammalian type H enzyme. In this regard, the aromatic nature of the C-7 ring as well as the presence and the position of the 4'-hydroxyl group contributed greatly to drug activity. Finally, the cytotoxicity of quinolones in the CP-115,953 series towards mammalian cells paralleled the in vitro stimulation of DNA cleavage by topoisomerase H rather than the inhibition of enzyme-catalyzed DNA relaxation. This correlation strongly suggests that these quinolones promote cell death by converting topoisomerase IT to a cellular poison.
DNA cleavage mediated by the type H enzyme with a potency that was -600-fold greater than that of the antimicrobial quinolone ciprofloxacin and -50-fold greater than that of the antineoplastic drug etoposide. As determined by the ability to enhance enzyme-mediated DNA cleavage, quinolone activity towards calf thymus topoisomerase H was enhanced by the presence of a cyclopropyl group at the N-1 ring position and by the presence of a fluorine at C-8. Furthermore, the 4'-hydroxyphenyl substituent at the C-7 position was critical for the potency of CP-115,953 towards the mammalian type H enzyme. In this regard, the aromatic nature of the C-7 ring as well as the presence and the position of the 4'-hydroxyl group contributed greatly to drug activity. Finally, the cytotoxicity of quinolones in the CP-115,953 series towards mammalian cells paralleled the in vitro stimulation of DNA cleavage by topoisomerase H rather than the inhibition of enzyme-catalyzed DNA relaxation. This correlation strongly suggests that these quinolones promote cell death by converting topoisomerase IT to a cellular poison.
Topoisomerase II is the target for a wide variety of clinically relevant antineoplastic drugs (21, 34) . A number of these compounds, including etoposide, amsacrine, doxorubicin, and mitoxantrone, currently are being used for the treatment of human cancers (21, 34) . Despite the structural diversity of topoisomerase II-targeted drugs, these agents share a common basis for their antineoplastic action. All of these drugs stabilize covalent enzyme-cleaved DNA complexes that are normal reaction intermediates in the catalytic cycle of topoisomerase 11 (21, 29, 34) . As a consequence of their action on enzyme-mediated DNA cleavage-religation, these drugs convert topoisomerase II into a cellular poison (20) and promote the formation of protein-associated breaks in the genomes of treated cells (21, 34) .
DNA gyrase, a prokaryotic type II topoisomerase (30, 36) , is also the target for a number of clinically important drugs (14, 22, 30, 43) . The most potent drug class targeted towards gyrase, the quinolones, contains some of the most active antimicrobial agents in use for the treatment of human infections (14, 43) . Like their antineoplastic counterparts, quinolone-based antimicrobial agents convert gyrase into a cellular poison by enhancing enzyme-mediated DNA breakage (14, 20, 22, 30, 36, 43) .
Quinolones have long been known to inhibit the overall catalytic activity of topoisomerase II, albeit at concentrations well above their therapeutic range (3, 8, 13, 15-17, * Corresponding author. [23] [24] [25] 27) . Recently, some of the more potent quinolonebased drugs, such as ciprofloxacin ( Fig. 1) and CP-67,015, also were reported to stimulate DNA cleavage mediated by the eukaryotic type II enzyme (3) . Since that initial report, a number of novel quinolones with activity against topoisomerase II, eukaryotic cells, or mammalian tumors have been described (8, 9, 18, 19, 31, 32, 37, (39) (40) (41) . In contrast to clinically relevant quinolone antimicrobial agents, many of these latter compounds contain an aromatic substituent at the C-7 position (3, 9, 18, 31, 32, 39, 40) .
The quinolone that displays the highest activity towards the eukaryotic type II enzyme is CP-115,953 [6,8-difluoro-7- (4'-hydroxyphenyl)-1-cyclopropyl-4-quinolone-3-carboxylic acid] (Fig. 1) (8, 31, 32) . This compound is cytotoxic towards mammalian cells and is the first quinolone-based drug reported to enhance topoisomerase II-mediated DNA breakage with a potency greater than that of a commonly used antineoplastic agent, such as etoposide (31) . Unlike etoposide (26, 33) , CP-115,953 and related compounds increase levels of DNA breakage without impairing the ability of the eukaryotic enzyme to religate cleaved nucleic acids (31, 32 It should be noted that topoisomerase II establishes DNA cleavage-religation equilibria both before and after its DNA strand passage event (29) . Since the enzyme requires ATP binding for strand passage and the assays described above were carried out in the absence of a high-energy cofactor, all of the data generated represent the pre-strand passage DNA cleavage reaction of topoisomerase II.
The term EC2 (effective concentration of drug required to enhance double-stranded DNA cleavage twofold) was used as a relative measure of quinolone stimulation of topoisomerase II-mediated DNA cleavage. First, as expected for drug-enzyme interactions, dose-response curves for quinolones were saturable. However, even for compounds with low activity against topoisomerase II, the dose-response curves in DNA cleavage assays generally were linear up to a twofold enhancement of enzyme-mediated DNA breakage. Thus, EC2 values were believed to reflect the initial slopes of drug concentration curves and hence drug potency. Second, compounds that were unable to double levels of DNA breakage when used at 500 ,M were believed to have marginal (at best) activity.
Topoisomerase lI-mediated DNA relaxation. DNA relaxation assays were carried out as described by Osheroff et al. (27) . Reaction mixtures contained 0.7 nM calf thymus topoisomerase II and 5 nM supercoiled pBR322 in a total volume of 20 pl of assay buffer that contained 1 mM ATP. DNA relaxation was carried out at 37°C for 15 min. Reactions were stopped by the addition of 3 ,l of 0.77% SDS-77 mM EDTA. Samples were mixed with 2 pl of loading buffer, heated for 2 min at 70°C, and subjected to electrophoresis on 1% agarose gels in Tris-borate (pH 8.3)-2 mM EDTA. DNA in the gels was visualized and quantitated as described above. The effects of drugs were examined over a concentration range of 0 to 500 pM. (13) . Even ciprofloxacin, the most active oral antimicrobial agent in clinical use (14, 43) , shows only low activity against calf thymus topoisomerase II. As shown in Fig. 2A , ciprofloxacin had little effect on enzyme-mediated DNA cleavage. The EC2 for this compound was 171 p,M (Table 1) . Furthermore, the ability of ciprofloxacin to inhibit the overall catalytic activity of the calf thymus enzyme (as monitored by a DNA relaxation assay) was considerably lower than that typically observed for most topoisomerase II-targeted antineoplastic drugs (21, 34) . The drug concentration required to inhibit DNA relaxation 50% (IC50) for ciprofloxacin was 106 F.M (Fig. 2B and Table 1 ).
In marked contrast to ciprofloxacin, quinolone CP-115,953 was a potent effector of mammalian topoisomerase II. As shown in Fig. 2A (ii) Ring position C-8. Previous studies suggest that the inclusion of a fluorine group at the C-8 position has little positive effect and in some cases has a detrimental effect on quinolone potency against DNA gyrase (6, 7, 32 ). In contrast, the C-8 fluorine enhances activity against Drosophila topoisomerase II -2.5-fold (32) . The presence of this fluorine group also led to a modest increase in potency against the mammalian enzyme ( Table 1 ). The substitution of a hydrogen for the fluorine at C-8 decreased the ability of difluorociprofloxacin (which is converted to ciprofloxacin by the removal of the fluorine) to enhance enzyme-mediated DNA cleavage -2.7-fold. Moreover, the potency of CP-115,953 (which is converted to CP-115,955 by the substitution) was reduced -13-fold. While a similar decrease in the ability to inhibit DNA relaxation was observed for CP-115,955, removal of the C-8 fluorine had little effect on the inhibitory properties of difluorociprofloxacin.
(iii) Ring position C-7. Although the N-1 cyclopropyl group and the C-8 fluorine group contribute to quinolone activity against mammalian topoisomerase II, they cannot account for the dramatic difference in potency found between CP-115,953 and the quinolone antimicrobial agents. However, substitution of a piperazine ring (difluorociprofloxacin) or a bromine (CP-151,774) for the 4'-hydroxyphenyl ring of CP-115,953 decreased the DNA cleavage-enhancing properties of the quinolone -200-or 21,900-fold, respectively. This finding strongly suggests that the C-7 ring substituent is critical for the activity of CP-115,953 against the mammalian enzyme. Since the C-7 substituent of CP-115,953 differs from the piperazine ring of difluorociprofloxacin primarily by its aromatic nature and by the presence of a 4'-hydroxyl group, these two features were examined for their contributions to drug activity.
To characterize the importance of aromaticity to quinolone function, the 4'-hydroxyphenyl ring was substituted for by a 4'-hydroxypiperidine group (converting CP-115,953
to CP-171,472). As shown in Table 1 , this substitution VOL. 37, 1993 Taken together, these results provide strong evidence that the aromatic nature of the C-7 ring substituent as well as the presence and the position of the 4'-hydroxyl group are critical for the potent enhancement of topoisomerase IImediated DNA cleavage by CP-115,953. While the ring substituents discussed above also appear to contribute to the inhibition of enzyme-catalyzed DNA relaxation by quinolones (Table 1) (31, 32) demonstrated that the substitution of an ethyl group for a cyclopropyl group at N-1 or the deletion of the C-8 fluorine decreased the in vivo potency of CP-115,953 -8-or -2-fold, respectively. Therefore, the present study was confined to examining the influence of the C-7 ring substituent. Cytotoxicity data for ciprofloxacin and etoposide were included, however, as controls.
The activity of quinolones in the CP-115,953 series against CHO cells is shown in Fig. 3 . As previously reported (31), the parent quinolone was equipotent to etoposide at killing this mammalian cell line. The drug concentration required to kill 50% of the cells (EC50) for CP-115,953 was -9 ,uM. In contrast, ciprofloxacin displayed little cytotoxicity towards CHO cells. At 500 ,uM ciprofloxacin (the highest drug concentration used), >80% of the cells remained viable.
As demonstrated for quinolone potency against mammalian topoisomerase II, the aromatic nature of the C-7 ring substituent and the presence and the position of the 4'-hydroxyl group on the C-7 substituent were important for the activity of CP-115,953 towards CHO cells. Substitution of the aromatic C-7 4'-hydroxyphenyl ring by either an aliphatic 4'-hydroxypiperidine group 472) (35, 42) and is supported by the fact that most quinolones with activity against the eukaryotic type II enzyme contain a C-7 ring with a hydrogen-bonding group either at the 4'-position (3, 19, (39) (40) (41) or as a substituent off the 4'-position (18, 31, 32, 41) . A second and intriguing possibility is that the C-7 4'-hydroxyphenyl ring mimics the active-site tyrosine of topoisomerase II (26, 29) 
